A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.

Celldex Therapeutics4 sites in 1 country28 target enrollmentDecember 2015

ConditionsAdvanced Cancer

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Advanced Cancer
Sponsor: Celldex Therapeutics
Enrollment: 28
Locations: 4
Primary Endpoint: Dose limiting toxicities for CDX-0158
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a dose-escalation Phase 1 study designed to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose, and the safety profile of CDX-0158 in patients with KIT-positive advanced solid malignancies refractory to standard therapy or for which no standard therapy exists.

Registry

clinicaltrials.gov

Start Date

December 2015

End Date

June 4, 2019

Last Updated

6 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Celldex Therapeutics

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Written informed consent and any locally required authorization (eg, HIPAA) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
•Metastatic or unresectable cancer that expresses KIT as documented in the patient's pathology report.
•For patients with GIST, patients will have progressed on at least one prior tyrosine kinase inhibitor therapy or be intolerant. If documented to have SDH deficient or PDGFRA-D842V GIST, no prior therapy is required for study entry. Other patients with KIT positive cancers will have progressed on at least one prior therapy.
•Patients must have at least 1 lesion that is measurable using RECIST guidelines.
•Females of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of effective contraception from screening, and must agree to continue using such precautions for 60 days after the final dose of study medication. Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or those who are postmenopausal (defined as 12 months with no menses without an alternative medical cause).
•Nonsterilized males who are sexually active with a female partner of childbearing potential must, with their partner, use 2 acceptable methods of effective contraception from Day 1 through 60 days after receipt of the final dose of study medication.
•ECOG status of 0 or
•Adequate organ function as defined below:
•Hemoglobin ≥ 9 g/dL. This criterion must be met without transfusion.
•Absolute neutrophil count ≥ 1500/mm3

Exclusion Criteria

•Receipt of anticancer therapy:
•Within 3 weeks prior to the first dose of CDX-0158 of any biologic treatment or IV chemotherapy.
•Within 2 weeks prior to the first dose of CDX-0158 of any oral therapy or 5.5 half lives whichever is longer or following palliative radiation therapy.
•Concurrent use of hormones for non-cancer related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable.
•Requirement for chronic immunosuppressive medication including systemic corticosteroids above the physiologic dose (30 mg/day hydrocortisone or the equivalent).
•Known allergy or past administration reaction including infusion related reaction (IRRs), anaphylactic, or anaphylactoid reactions to any component of the CDX-0158 formulation.
•History of clinically significant allergic reactions or atopic disease that may pose an increased risk of severe CDX-0158 IRRs.
•Symptomatic or untreated central nervous system metastases requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids; if treated, patient must be asymptomatic for 3 months prior to study entry.
•Other invasive malignancy within 2 years prior to enrollment (localized prostate cancer, cervical carcinoma in situ, non-melanoma skin cancer, or ductal carcinoma in situ of the breast that has/have been surgically cured would not be exclusionary).
•Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v 4.03 \< Grade 2 or normalized to baseline, or to levels dictated in the inclusion/exclusion criteria, with the exception of alopecia.